530 results on '"Janusz K. Rybakowski"'
Search Results
452. The effect of treatment with risperidone, olanzapine or phenothiazines on cognitive functions in patients with schizophrenia
453. P-2-63 changes in acute phase proteins in depressed patients, during treatment with fluoxetine and venlafaxine
454. P.2.033 Quality of life of patients with schizophrenia measured by schizophrenia quality of life scale
455. P.6.047 No association between DRD2 and DRD3 gene polymorphism and bipolar affective disorder
456. P.2.096 No association between serotonin transporter polymorphism and schizophrenia
457. P.1.235 Frequency of bipolar disorder spectrum in patients with first episode of depression and recurrent depression
458. P.2.088 Dopaminergic system genes and performance on prefrontal test in schizophrenia
459. P.6.048 BDNF Val66Met polymorphism in bipolar affective disorder and schizophrenia — association with early age of onset in schizophrenia
460. Cytosolic phospholipase A2 gene polymorphism and eye movement disturbances in schizophrenia
461. Is quality of life in dementia associated with severity of depression or cognitive deficits?
462. HLA antigenes in schizophrenia: relation to eye movement disturbances
463. Acceptance of pharmacological treatment by schizophrenic patients
464. Gender differences in spectral EEG analysis during exacerbation of schizophrenia
465. TNF alpha polymorphism in mothers of schizophrenia patients
466. Eye movement disturbances and dopamine D3 receptor gene
467. Altered microheterogeneity of α1-acid glycoprotein in endogenous depression
468. Treating prodromal symptoms of schizophrenia in high-risk subjects with low dose risperidone
469. Cognitive functions in hyperthyroid patients
470. Association between MAO-A gene promoter VNTR polymorphism and female bipolar patients
471. The effects of lithium and carbamazepine on selected immunological indices in affective patients
472. P02.249 Factors associated with therapeutic effect of risperidone on psychopathology and working memory in schizophrenic patients
473. The effect of atypical vs typical antipsychotic drugs on the results of neurocognitive tests in schizophrenic patients
474. Subjective experiences of schizophrenic patients on atypical antipsychotic olanzapine and typical antipsychotic perphenazine
475. The effect of risperidone on schizophrenic symptoms and eye movement disturbances
476. The effect of treatment with risperidone vs phenothiazine neuroieptics on eye tracking of schizophrenic patients during two fixation tasks
477. Concentration and microheterogeneity glycophorms of haptoglobin and transferrin in schizophrenia
478. Indicators of chronic immune activation in schizophrenia
479. The effect of treatment with typical and atypical neuroleptic drugs on neuropsychological measurements in patients with schizophrenia
480. Psychological and clinical factors predicting alcohol abstinence during 16-weeks treatment with lithium carbonate
481. P.2.055 Acute phase proteins in major depressed and schizophrenic patients during acute episode of the illness
482. P.1.111 Relationships between selected immunological parameters and cortisol in treatment resistant depression
483. Total serum protein and seerum protein fractions in major and treatment resistant depression
484. Author Index (Abstracts)
485. Anxiolytic and Memory Improving Activity of Moclobemide
486. Changes in immunological parameters in refractory depression
487. The effects of potentiation with lithium of antidepressant drugs on immunological indices in refractory depression
488. P-21 Augmentation of antidepressant response by lithium — changes in acute phase proteins
489. P-34 Memory improving activity of fluoxetine in humans and rats
490. ECG estimation of patients with bipolar affective illness treated for over 10 years with lithium
491. Alterations in immunological indices in depression
492. Clinical an psychometrical correlates of alcohol craving in alcohol dependent male inpatients
493. Anomalies of dermatoglyphics in patients with schizophrenia
494. Some interleukins, their receptors and alpha-1-acid glycoprotein as the indicators of immune activation in major depression
495. Subject Index Vol. 63, 1995
496. The effects of treatment with lithium and carbamazepine on some interleukins and their receptors in depressed patients
497. Types of Depression More Frequent in Bipolar than in Unipolar Affective Illness: Results of the Polish DEP-BI Study.
498. PLASMA IMMUNOGLOBULINS DURING LITHIUM AND CARBAMAZEPINE TREATMENT
499. High prevalence of alexithymia in male patients with alcohol dependence
500. Alexithymia and Somatic Conditions in Patients with Affective Illnesses during Lithium Prophylaxis
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.